A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess Efficacy, Safety and Tolerability of BMB-101 Oral Solution for the Treatment of Patients with Prader-Willi Syndrome [PWS] (NCT07266324)

Phase 2 trial for patients diagnosed with Prader Willi Syndrome using oral study medication.

Trial phase

Phase 2

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Dr Daniel Fineberg

Key inclusion data

Males and females aged 18-65 inclusive. Genetically confirmed diagnosis of Prader Willi Syndrome via standard DNA testing or other commonly approved methods. Willing and able to provide voluntary written informed consent, or have a Legally Authorized. Representative who is able to provide consent. Participant and/or caregiver has the ability to be compliant with study requirements, including visit schedule, diary completion and study drug accountability.